Sage Therapeutics has a unique approach to targeting GABA, which allows it to target CNS disorders. Its main asset is Zurzuvae, which is co-marketed with Biogen for PPD. BIIB recently made a bid for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback